Many of the most-read articles from the print issues of Managed Healthcare Executive® focused on the cost of therapies.
Governments are the only buyers so far, and the amounts they are paying varies.
Screening and some care have been canceled or deferred. Will more illness and deaths result?
Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.
PBMs say exclusions are important for negotiating lower prices on behalf of health plans and members. Some payer and provider groups say they interfere with patient access to medicines.
Having specialty pharmacies fill prescriptions may lower costs, but critics of the practice see safety issues and other drawbacks.
HIV Antiretroviral Reduced Alzheimer’s Risk Continuously, Study Shows
May 8th 2025Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen